



# JAGSONPAL PHARMACEUTICALS LIMITED

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



July 26, 2025

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Subject: Outcome of Board Meeting held on July 26, 2025 along with Unaudited Financial Results for the quarter ended June 30, 2025**

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2025.

In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2025.

The Board Meeting commenced at 11:55 A.M. and concluded at 12:30 P.M.

We request you to take the above on record.

Thanking you,

Yours faithfully,

**For Jagsonpal Pharmaceuticals Limited**

**Pratham Rawal**  
**Company Secretary & Compliance Officer**

**Regd. Office:** Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)  
**Mumbai Office:** 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070

# Walker ChandioK & Co LLP

Walker ChandioK & Co LLP  
21<sup>st</sup> Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram – 122 002  
India

T +91 124 4628099  
F +91 124 4628001

## Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Jagsonpal Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Jagsonpal Pharmaceuticals Limited ('the Company') for the quarter ended 30 June 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



#### Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

# Walker ChandioK & Co LLP

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

*Madhu Sudan*

Madhu Sudan Malpani

Partner

Membership No. 517440

UDIN: 25517440BMLKFF8215

Place: Gurugram

Date: 26 July 2025



# Jagsonpal Pharmaceuticals Limited

Corporate office: Plot No. 412-415, 3rd Floor, Nimai Tower, Phase- IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015

CIN No:- L74899DL1978PLC009181

Phone: 0124-4406710

## Statement of Unaudited Financial Results for the Quarter Ended 30 June 2025

(Rs. in Million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited) (Refer note 5)	(Unaudited)	(Audited)
		2025	2025	2024	2025
	<b>INCOME</b>				
1	Revenue from operations	756.12	585.60	614.39	2,687.16
2	Other income	28.25	27.70	14.44	81.90
3	<b>Total income (1+2)</b>	<b>784.37</b>	<b>613.30</b>	<b>628.83</b>	<b>2,769.06</b>
4	<b>EXPENSES</b>				
	a) Cost of materials consumed	53.32	34.85	43.87	183.43
	b) Purchases of stock-in-trade	226.89	174.97	200.34	802.21
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(10.94)	7.38	(21.17)	(21.26)
	d) Employee benefits expense	179.44	155.82	148.91	641.29
	e) Share based payment expense	14.97	9.86	24.25	68.04
	f) Finance costs	2.54	2.59	2.15	9.58
	g) Depreciation and amortisation expense	23.53	23.05	10.72	81.31
	h) Other expenses	150.31	115.58	115.81	502.74
	<b>Total expenses</b>	<b>640.06</b>	<b>524.10</b>	<b>524.88</b>	<b>2,267.34</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>144.31</b>	<b>89.20</b>	<b>103.95</b>	<b>501.72</b>
6	<b>Exceptional items (net)</b>	-	(2.12)	(32.85)	196.87
7	<b>Profit before tax (5+6)</b>	<b>144.31</b>	<b>87.08</b>	<b>71.10</b>	<b>698.59</b>
8	<b>Tax expense:</b>				
	Current tax (including earlier years)	31.71	12.39	15.87	135.72
	Deferred tax charge	4.65	8.86	1.94	9.26
9	<b>Net profit for the period/year (7-8)</b>	<b>107.95</b>	<b>65.83</b>	<b>53.29</b>	<b>553.61</b>
10	<b>Other comprehensive income (OCI)</b>				
	i) a) Items that will not be reclassified to profit or loss	-	-	-	-
	- Remeasurement (loss)/gain on defined benefit obligations	0.76	(3.88)	(0.64)	2.92
	b) Income tax relating to items that will not be reclassified to profit or loss	(0.19)	0.98	0.16	(0.73)
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
11	<b>Total comprehensive income for the period/year (9+10)</b>	<b>108.52</b>	<b>62.93</b>	<b>52.81</b>	<b>555.80</b>
12	<b>Earnings per share (not annualised for the quarters) (Refer Note 6)</b>				
	Basic (Rs.)	1.60	0.98	0.78	8.26
	Diluted (Rs.)	1.58	0.98	0.77	8.22
13	<b>Paid-up equity share capital (face value per share Rs. 2) (Refer Note 6)</b>	<b>133.06</b>	<b>132.80</b>	<b>132.29</b>	<b>132.80</b>
14	<b>Reserves excluding revaluation reserves (other equity)</b>				<b>2,266.70</b>
	<b>See accompanying notes to the Financial Results</b>				



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**





**Notes to the unaudited financial results:**

1. The unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers in India and overseas, which is being considered as a single reportable business segment by the chief operating decision maker.
3. Subsequent to the quarter end, on 08 July 2025, Sachin Jain ceased to be the Chief Financial Officer (Key Managerial Personnel) of the Company following his release from service during the probation period. The Company is in process of hiring a new Chief Financial Officer within the expected timelines of the Companies Act, 2013.
4. During the quarter, the Company has granted 37,500 stock options to the eligible employees as determined by the Nomination and Remuneration Committee of the Company and has allotted 127,850 equity shares under the Company's Employee Stock Option Plan 2022 on exercise of vested options by eligible employees.
5. The figures for the quarter ended 31 March 2025, as reported in the financial results, are the balancing figures between the audited figures for the year ended 31 March 2025 and the published year to date figures for 31 December 2024, which were subjected to limited review by the statutory auditor.
6. During the previous year, pursuant to the resolution passed by the Board of Directors on 23 October 2024, the Company approved the sub-division/split of existing equity shares having a face value of ₹ 5 each, fully paid up, into such number of equity shares having face value of ₹ 2 each fully paid-up. During the quarter, as prescribed under Ind AS, the Company has presented restated basic and diluted earnings per share basis for previous period.
7. The above financial results for the quarter ended 30 June 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26 July 2025 and a limited review of the same has been carried out by the statutory auditors.
8. The Board of Directors at their meeting held on 06 May 2025 have recommended a final dividend of ₹ 2.5 per equity share (of ₹ 2 each) amounting to ₹166.00 million for the year ended 31 March 2025 subject to approval in Annual General Meeting.
9. Previous periods figures have been regrouped/reclassified to confirm to the current period classification.

Place : Gurugram  
Date : 26 July 2025

*Manish*

**Manish Gupta**  
Managing Director



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**

